• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ABEMACICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • ABEMACICLIB chembl:CHEMBL3301610 ApprovedAntineoplastic

    Alternate Names:

    VERZENIO
    ABEMACICLIB
    VERZENIOS
    LY-2835219
    HY-16297A
    LY2835219
    CS-1230
    LY 2835219
    chembl:CHEMBL3301610
    pubchem.compound:46220502
    chemidplus:1231929-97-7
    drugbank:12001

    Drug Info:

    Pharmaceutical Developer Eli Lilly
    Source Reported Drug Name(s) LY2835219
    Drug Class CDK/Rb Inhibitor
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational
    Drug Categories amines
    Drug Categories antineoplastic agents
    Drug Categories antineoplastic and immunomodulating agents
    Drug Categories bcrp/abcg2 inhibitors
    Drug Categories bcrp/abcg2 substrates
    Drug Categories cytochrome p-450 cyp1a2 inhibitors
    Drug Categories cytochrome p-450 cyp1a2 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2b6 inhibitors
    Drug Categories cytochrome p-450 cyp2b6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c8 inhibitors
    Drug Categories cytochrome p-450 cyp2c8 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c9 inhibitors
    Drug Categories cytochrome p-450 cyp2c9 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2d6 inhibitors
    Drug Categories cytochrome p-450 cyp2d6 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a inhibitors
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories kinase inhibitor
    Drug Categories mate 1 inhibitors
    Drug Categories mate 1 substrates
    Drug Categories mate 1 substrates with a narrow therapeutic index
    Drug Categories mate 2 inhibitors
    Drug Categories mate inhibitors
    Drug Categories mate substrates
    Drug Categories oct2 inhibitors
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories protein kinase inhibitors
    Drug Categories pyridines
    (9 More Sources)

    Publications:

    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.
    Gelbert et al., 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine., Invest New Drugs
    Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
    Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun
  • ABEMACICLIB   SMARCA4

    Interaction Score: 1.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718512 30718506


    Sources:
    CIViC

  • ABEMACICLIB   CCND2

    Interaction Score: 1.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   CCND3

    Interaction Score: 1.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   CDK6

    Interaction Score: 1.28

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction CDK6/cyclin D1 complex expressed in and purified from insect cells. Assays used the methanesulfonate salt of the compound.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    24919854


    Sources:
    CancerCommons TTD DrugBank GuideToPharmacology ChemblInteractions

  • ABEMACICLIB   CDK4

    Interaction Score: 0.98

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction CDK4/cyclin D1 complex expressed in and purified from insect cells. Assays used the methanesulfonate salt of the compound.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    24919854


    Sources:
    ClearityFoundationBiomarkers CancerCommons OncoKB TTD DrugBank GuideToPharmacology ChemblInteractions

  • ABEMACICLIB   CDKN2A

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27217383 26183925


    Sources:
    ClearityFoundationBiomarkers OncoKB JAX-CKB

  • ABEMACICLIB   CCND1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • ABEMACICLIB   KRAS

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Evidence Type Actionable
    Approval Status Phase I

    PMIDs:
    1291017 27217383 26658964


    Sources:
    JAX-CKB CIViC CGI

  • ABEMACICLIB   NRAS

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27217383


    Sources:
    JAX-CKB

  • ABEMACICLIB   ERBB2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration ERBB2:norm;ESR1:over
    Drug family CDK4/6 inhibitor

    PMIDs:
    None found


    Sources:
    FDA PharmGKB CGI

  • ABEMACICLIB   PGR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ABEMACICLIB   ESR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family CDK4/6 inhibitor
    Alteration ERBB2:norm;ESR1:over

    PMIDs:
    None found


    Sources:
    FDA PharmGKB CGI

  • ABEMACICLIB   ESR2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ABEMACICLIB   TP53

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family CDK4/CDK6 inhibitor
    Alteration TP53:.
    Indication/Tumor Type colorectal cancer

    PMIDs:
    27217383


    Sources:
    JAX-CKB CGI

  • DrugBank: DB12001

    • Version: 5.1.7

    Alternate Names:
    ABEMACICLIB DrugBank Drug Name
    1231929-97-7 CAS Number
    Verzenio Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Gelbert et al., 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine., Invest New Drugs

  • CancerCommons: LY2835219

    • Version: 25-July-2013

    Alternate Names:
    LY2835219 Drug Trade Name
    LY2835219 Drug Development Name

    Drug Info:
    Drug Class CDK/Rb Inhibitor
    Source Reported Drug Name(s) LY2835219
    Pharmaceutical Developer Eli Lilly

    Publications:

  • CGI: Abemaciclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
    Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov

  • JAX-CKB: Abemaciclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.

  • CIViC: ABEMACICLIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun

  • TTD: LY2835219

    • Version: 2020.06.01

    Alternate Names:
    D05SBO TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 178103954

    • Version: 29-September-2020

    Alternate Names:
    ABEMACICLIB GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3301610

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3301610

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: abemaciclib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: LY2835219

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Abemaciclib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Abemaciclib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21